Signal Genetics, which develops and sells cancer diagnostics, submitted an initial filing and announced terms for its IPO on Wednesday. The New York, NY-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Signal Genetics would command a market value of $53 million.
Signal Genetics, which was founded in 2010 and booked $4 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol SGNL. Signal Genetics initially filed confidentially on November 12, 2013. Aegis Capital is the sole bookrunner on the deal.
